Boston, Mass., Nov 29, 2021 — HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-class allosteric therapies targeting regulatory sites on proteins referred to as “natural hotspots,” today announced the close of its oversubscribed $100 million Series C financing, bringing its total funding to $190 million.
HotSpot Therapeutics, the allostery-focused biotech that works on what it calls “natural hotspots” — hence the name — is getting a bit hotter in its valuation from investors. And to that end they’ve raised $100 million. The four-year-old AI computational biotech started by two former Nimbus execs announced this morning that it closed its Series C round right at the line of a 9-figure investment, courtesy of some big investors.
SAN DIEGO–(BUSINESS WIRE)–Engrail Therapeutics™ (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies and The Texas A&M University System (TAMUS),
Director Technology – Pivotal Life Sciences
Hong Kong Life Sciences Society
Hong Kong Life Sciences Society (HKLSS) is a non profit youth organization established in 2018 aiming to build a dynamic life sciences ecosystem in Hong Kong.
Through knowledge exchange, collaboration and public engagement, HKLSS has been committed to nurture talent that helps develop a world-class life sciences industry cluster in Hong Kong.
The D. H. Chen Foundation
The D. H. Chen Foundation is a private philanthropic organization founded in 1970 by Dr. Din Hwa CHEN, who also established the Nan Fung Group. Over the past decades, the Foundation has been supporting numerous worthy community philanthropic initiatives to promote compassion-based values.
To this day, Dr. Chen’s philanthropic vision continues to drive the Foundation’s work efforts. Aspiring to build a compassionate society, the Foundation has been endeavoring to steer innovative, impactful and sustainable initiatives to realize Dr. Chen’s philosophy “Care for others as well as you would care for yourself.”
Hong Kong Life Sciences Society
Hong Kong Life Sciences Society (HKLSS) is a non profit youth organization established in 2018 aiming to build a dynamic life sciences ecosystem in Hong Kong.
Through knowledge exchange, collaboration and public engagement, HKLSS has been committed to nurture talent that helps develop a world-class life sciences industry cluster in Hong Kong.
The D. H. Chen Foundation
The D. H. Chen Foundation is a private philanthropic organization founded in 1970 by Dr. Din Hwa CHEN, who also established the Nan Fung Group. Over the past decades, the Foundation has been supporting numerous worthy community philanthropic initiatives to promote compassion-based values.
To this day, Dr. Chen’s philanthropic vision continues to drive the Foundation’s work efforts. Aspiring to build a compassionate society, the Foundation has been endeavoring to steer innovative, impactful and sustainable initiatives to realize Dr. Chen’s philosophy “Care for others as well as you would care for yourself.”
Senior Associate – Pivotal Life Sciences
Executive Assistant – Pivotal bioVenture Partners (US)
Executive Assistant – Pivotal bioVenture Partners (US)
Executive Coordinator – Pivotal Life Sciences
Data Scientist Engineer – Pivotal Life Sciences
Chief Science Officer – Pivotal Life Sciences
Kai Chen
Senior Associate
Kai Chen is a Senior Associate with Pivotal bioVenture Partners China. Prior to joining Pivotal China, Kai was an Associate Director at CStone Pharmaceutical, in charge of Commercial Strategy and New Product Planning. He supported the entire process of commercial launch of two precision oncology products (Ayvakit, Gavreto) and the CStone-Pfizer strategic partnership deal. Prior to CStone, Kai was a Consultant at BCG Greater China Office focusing on healthcare. He has also worked as a Business Development Associate at Simcere Pharmaceuticals US. Kai received his Ph.D. in Chemistry from the University of Chicago (advisor: Prof. Chuan He) and his B.S. in Chemical Biology from Tsinghua University.
SVP, Head of Investor Relations – Pivotal Life Sciences
Benjamin Li
Bibhash Mukhopadhyay
Bibhash is a Partner with Pivotal CNS. Prior to joining the NFLS platform of funds, he was a Principal at NEA where he acquired investing, portfolio management and board leadership experience in a number of private and public biotech companies across various stages, geographies and therapeutic areas. Prior to that, he worked in BD and Corporate Strategy at Astra Zeneca and before that, at Johnson & Johnson. In those roles, he led a number of transactions in pre-clinical and clinical stage assets.
Bibhash did his PhD research on retinal degeneration from Baylor College of Medicine Houston USA, has a Masters in Neuroscience from Max Planck Research School in Germany and an undergrad degree in biomedical sciences from India.
Zhilei Guo
Executive director
Zhilei joined PivotalChina as Executive director in 2021. Prior to that, he was Executive Director in Epiphron Capital and Vice President in Cathay Capital Private Equity focusing on healthcare investment in Shanghai. Before started his investment professional career, Zhilei was with Sanofi and Abbott (Abbvie) in different roles of Medical Affairs, Product Launch, and Business Strategy and Development. He practiced as a neurosurgeon in Huashan Hospital affiliated to Fudan University after graduation.
Zhilei received his Doctor of Medicine and second bachelor of Economics from Fudan University. He also holds an MBA from CEIBS and MPH from the Johns Hopkins University Bloomberg School of Public Health.
Kwok Yung Yuen
Advisor – Nan Fung Life Sciences
Margie Tostado
Executive Assistant
Melissa Cheng
Executive Assistant
Melissa joined Pivotal in 2018. She assists with the administration and support for the office. Prior to joining Pivotal, she has worked as an Executive Assistant supporting C-level executives in venture capital, tech and real estate investment. Melissa studied at San Francisco State University and majored in Business Administration.
Advisor – Nan Fung Life Sciences
Vice President – Pivotal Life Sciences, Pivotal bioVenture Partners (China)
Advisor – Nan Fung Life Sciences
Operating Partner – Pivotal Life Sciences, Pivotal bioVenture Partners (China)
Advisor – Nan Fung Life Sciences
Partner – Pivotal Life Sciences & Pivotal bioVenture Partners (China)
Antony Leung
Chairman & CEO – Nan Fung Group
Senior Associate – Pivotal Life Sciences, Pivotal bioVenture Partners (China)
Partner -Nan Fung Life Sciences, Pivotal Life Sciences & Pivotal Growth
Executive Director – Nan Fung Life Sciences, Pivotal Life Sciences
Executive Assistant to Group MD & COO – Nan Fung Group
Vice President – Nan Fung Life Sciences, Pivotal Growth & Pivotal Life Sciences
Managing Director – Nan Fung Life Sciences, Pivotal Life Sciences, Pivotal Growth & Pivotal bioVenture Partners (US)
Mr. Bisgaard joined Nan Fung and Pivotal Life Sciences in 2017. He was previously a Senior Partner at Novo Ventures (US) Inc. since 2009. As part of Novo’s senior team, he was responsible for Novo Ventures’ overall investment and portfolio strategy as well as the ongoing development of the Novo Ventures team in the US. Prior to that, Mr. Bisgaard was with Novo A/S since 2001 in Denmark. He has both investment and board experience from a large number of private and public US life sciences companies. Prior to joining Novo A/S, Peter was with McKinsey & Co. as a general consultant and as a specialist within the Scandinavian Corporate Finance and Strategy Group. He was part of the strategic and financial advisory teams in multiple large Private Equity and Corporate M&A transactions and strategy projects across industry sectors. Mr. Bisgaard obtained an M.Sc. in Engineering in 1998 from the Technical University of Denmark and was awarded a post-graduate degree in Mathematical Modelling in Economics by the European Consortium for Mathematics in the Industry.
Managing Partner – Pivotal bioVenture Partners (US)
Advisor – Pivotal Life Sciences, Pivotal bioVenture Partners (China)
Operating Partner – Pivotal bioVenture Partners (China)
Chief Executive Officer – Nan Fung Life Sciences, Managing Partner – Pivotal Life Sciences, Managing Director and Chief Operating Officer – Nan Fung Group, & Founder and Managing Partner – Pivotal bioVenture Partners (China & US)
Director Finance – Nan Fung Life Sciences, Pivotal Life Sciences & Pivotal bioVenture Partners (China)
Senior Finance Manager – Pivotal Life Sciences & Pivotal bioVenture Partners (China)
Vice President – Nan Fung Group & Pivotal Life Sciences
Director – Pivotal Life Sciences & Public Investing
Chief Investment Officer – Nan Fung Group, Managing Director – Pivotal Life Sciences & Managing Partner – Pivotal bioVenture Partners (US) & (China)
Advisor – Nan Fung Life Sciences, Venture Partner – Pivotal bioVenture Partners (US)
Human Resources, Office Manager – Pivotal Life Sciences
Business Analyst – Pivotal Life Sciences & Pivotal bioVenture Partners (China)
Davis Yang
Investment Director – Nan Fung Life Sciences,Pivotal Life Sciences & Operating Partner – Pivotal bioVenture Partners (China)
Director of Human Resources NFLS, Pivotal China
Ash Khanna
Partner – Pivotal bioVenture Partners (US)
